ArticleCell reports. Medicine2021
Broad auto-reactive IgM responses are common in critically ill patients, including those with COVID-19.
Article in Cell reports. Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- Clonal landscape of autoantibody-secreting plasmablasts in COVID-19 patients.Life science alliance · 2024Article
- A multimodal integration pipeline for accurate diagnosis, pathogen identification, and prognosis prediction of pulmonary infections.Innovation (Cambridge (Mass.)) · 2024Article
- Prevalence of anti-lymphocyte IgM autoantibodies driving complement activation in COVID-19 patients.Frontiers in immunology · 2024Article
- Is there an immunological cross-reactivity of antibodies to the myelin oligodendrocyte glycoprotein and coronaviruses?Brain communications · 2024Article
- The immunology of long COVID.Nature reviews. Immunology · 2023Review
- Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection.Nature reviews. Immunology · 2023Review
- Complement C3 inhibition in severe COVID-19 using compstatin AMY-101.Science advances · 2022Article
- A public antibody class recognizes an S2 epitope exposed on open conformations of SARS-CoV-2 spike.Nature communications · 2022Article
- Response under pressure: deploying emerging technologies to understand B-cell-mediated immunity in COVID-19.Nature methods · 2022Article
- Long-Term Effects of COVID-19.Mayo Clinic proceedings · 2022Review
- Antigenic Cross-Reactivity Between SARS-CoV-2 S1-RBD and Its Receptor ACE2.Frontiers in immunology · 2022Article
- A flow-cytometry-based protocol using diverse cell types for detecting autoantibodies from human plasma and serum samples.STAR protocols · 2021Article
Corrections and comments
- Update of
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
The pathogenesis of severe coronavirus disease 2019 (COVID-19) remains poorly understood. While several studies suggest that immune dysregulation plays a central role, the key mediators of this process are yet to be defined. Here, we demonstrate that plasma from a high proportion (93%) of critically ill COVID-19 patients, but not healthy controls, contains broadly auto-reactive immunoglobulin M (IgM) and less frequently auto-reactive IgG or IgA. Importantly, these auto-IgMs preferentially recognize primary human lung cells
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.